


Phenylbutazone

Cat. No.:	HY-B0230
CAS No.:	50-33-9
Molecular Formula:	C ₁₉ H ₂₀ N ₂ O ₂
Molecular Weight:	308.37
Target:	COX
Pathway:	Immunology/Inflammation
Storage:	<div> <div>Powder</div> <div>-20°C 3 years</div> <div>4°C 2 years</div> </div> <div> <div>In solvent</div> <div>-80°C 2 years</div> <div>-20°C 1 year</div> </div>



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (324.28 mM)
H₂O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.2428 mL	16.2141 mL	32.4281 mL
	5 mM		0.6486 mL	3.2428 mL	6.4856 mL
	10 mM		0.3243 mL	1.6214 mL	3.2428 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (8.11 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.11 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research^{[1][2]}.

In Vitro

Phenylbutazone has low inhibition of COX-1 and COX-2^[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Beretta C, et al. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. *Pharmacol Res.* 2005 Oct;52(4):302-6.
- [2]. G A Reed, et al. Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism. *Mol Pharmacol.* 1985 Jan;27(1):109-14.
- [3]. Guiying Chen, et al. Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy. *Sci Rep.* 2016 Apr 29;6:25317.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA